In the News
In the News
Speeding up the
delivery of
Alzheimer’s &
Parkinson’s treatments.
GAP and our 100+ clinical research partners are collaborating to speed the delivery of innovative CNS therapies and treatments by reducing the time and cost of Alzheimer’s and other CNS clinical trials and with a commitment to diversity in research and ensuring there are options that work for all.
0+
Research Sites
Now Available
Featured · Bio-Hermes
Bio-Hermes biospecimens are now available for sale.
Plasma, serum, and PBMC samples from the largest blood-based biomarker study in Alzheimer’s research — ready to accelerate your discovery work.
Why this matters
A generation is waiting for more options and more time.
Nearly 0M
Americans currently living with Alzheimer's disease.
0%
Increase in deaths from Alzheimer's between 2000 and 2024.
$0B
Estimated cost of Alzheimer's and other dementias in the U.S. in 2026.
Our Global Network
Global network of research sites working in concert.
GAP-Net connects leading private and academic research sites across North America, the United Kingdom, and Europe — every dot below is an active site that is or has run neurodegenerative trials with us.
Through our Trial Execution Services (TES) teams, GAP Participant Services (GPS Liaisons) and our Inclusive Research Initiative (Community Connectors), research opportunities extend beyond the research site, into communities and improving access to cutting edge science and technology.
Learn more about our Trial Execution Services
Since 2016
Building a foundation for faster trials.
A track record of supporting industry-funded studies and initiating GAP-sponsored research that the field needs.
EST. 2016
2016
GAP Foundation begins coordinating clinical trial sites.
SUPPORTED
0+
GAP-enabled and GAP-sponsored studies since 2018.
INITIATED
0
GAP-Sponsored studies launched, including Bio-Hermes.
DEPLOYED
0+
GPS & IRI visits since 2018 connecting volunteers to trials.
TODAY
0+
Active GAP-Net research sites worldwide.
Press & Media
